Evotec/$EVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evotec
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Ticker
$EVO
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
4,766
ISIN
US30050E1055
Website
Evotec Metrics
BasicAdvanced
$1.3B
-
-$1.35
1.09
-
Price and volume
Market cap
$1.3B
Beta
1.09
52-week high
$5.48
52-week low
$2.84
Average daily volume
166K
Financial strength
Current ratio
2.028
Quick ratio
1.749
Long term debt to equity
45.803
Total debt to equity
52.482
Interest coverage (TTM)
-7.04%
Profitability
EBITDA (TTM)
1.343
Gross margin (TTM)
13.62%
Net profit margin (TTM)
-26.26%
Operating margin (TTM)
-10.22%
Effective tax rate (TTM)
-5.04%
Revenue per employee (TTM)
$195,960
Management effectiveness
Return on assets (TTM)
-2.42%
Return on equity (TTM)
-20.51%
Valuation
Price to revenue (TTM)
0.775
Price to book
1.28
Price to tangible book (TTM)
1.93
Price to free cash flow (TTM)
-8.011
Free cash flow yield (TTM)
-12.48%
Free cash flow per share (TTM)
-49.56%
Growth
Revenue change (TTM)
1.50%
Earnings per share change (TTM)
128.61%
3-year revenue growth (CAGR)
6.66%
10-year revenue growth (CAGR)
23.77%
3-year earnings per share growth (CAGR)
30.40%
10-year earnings per share growth (CAGR)
43.89%
What the Analysts think about Evotec
Analyst ratings (Buy, Hold, Sell) for Evotec stock.
Bulls say / Bears say
Evotec's strategic partnership with Bristol Myers Squibb has led to significant advancements in developing molecular glue degraders, resulting in performance-based payments totaling $75 million to Evotec. (finviz.com)
The company has refocused its strategy towards more profitable segments, aiming for an adjusted EBITDA margin above 20% by 2028, surpassing analysts' expectations. (tradingview.com)
Evotec's Just - Evotec Biologics division continues to show strong growth momentum, with external revenues increasing by 11% in Q1 2025 compared to the same period in 2024. (finviz.com)
BofA Securities downgraded Evotec's price target from $4.50 to $3.00, citing underwhelming quarterly performance and a lack of positive outlook. (investing.com)
The company plans to reduce its workforce by approximately 400 roles (7% of the workforce) due to challenging revenues and profitability, indicating operational difficulties. (benzinga.com)
Jefferies Financial Group downgraded Evotec from a 'buy' to a 'hold' rating, lowering the target price from $8.70 to $3.80, reflecting diminished confidence in the company's near-term prospects. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Evotec Financial Performance
Revenues and expenses
Evotec Earnings Performance
Company profitability
Evotec News
AllArticlesVideos
Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments
Accesswire·1 month ago
Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment
Accesswire·1 month ago
Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evotec stock?
Evotec (EVO) has a market cap of $1.3B as of June 20, 2025.
What is the P/E ratio for Evotec stock?
The price to earnings (P/E) ratio for Evotec (EVO) stock is 0 as of June 20, 2025.
Does Evotec stock pay dividends?
No, Evotec (EVO) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Evotec dividend payment date?
Evotec (EVO) stock does not pay dividends to its shareholders.
What is the beta indicator for Evotec?
Evotec (EVO) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.